Serbian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Individual Differences in Glucosamine Sulfate Exposure Levels

Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Веза се чува у привремену меморију
Статус
Спонзори
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Кључне речи

Апстрактан

Glucosamine is an important part of the treatment strategy for osteoarthritis, but its effectiveness is still controversial. To explain the efficacy differences of glucosamine, in this study the investigators detect the concentration of glucosamine in the plasma and synovial fluid, some effect indexes such as inflammatory markers and gene polymorphism of glucosamine transporters. On the one hand, the investigators compare the plasma peak and gluten glucosamine concentration and the concentration in synovial fluid among participants to observe the individual differences of glucosamine exposure in vivo. On the other hand, the investigators investigate the correlation between drug concentrations, effect index and gene polymorphism. The hypothesis is that glucosamine exposure in vivo has individual differences and gene polymorphism can explain this differences.

Датуми

Последња верификација: 06/30/2017
Фирст Субмиттед: 06/22/2017
Предвиђена пријава послата: 06/26/2017
Прво објављено: 06/27/2017
Послато последње ажурирање: 07/02/2017
Последње ажурирање објављено: 07/04/2017
Стварни датум почетка студије: 07/01/2017
Процењени датум примарног завршетка: 06/30/2019
Предвиђени датум завршетка студије: 09/30/2019

Стање или болест

Knee Osteoarthritis

Интервенција / лечење

Drug: Drug group

Фаза

-

Групе руку

АрмИнтервенција / лечење
Drug group
patients taking glucosamine
Drug: Drug group
Patients taking glucosamine sulfate 1500mg every day for at least four days.

Критеријуми

Узраст подобан за студирање 60 Years До 60 Years
Полови подобни за студирањеAll
Метода узорковањаNon-Probability Sample
Прихвата здраве волонтереда
Критеријуми

Inclusion Criteria:

1. patients undergoing total knee arthroplasty for knee osteoarthritis;

2. 60-80 years.

Exclusion Criteria:

1. patients with severe liver or renal insufficiency;

2. patients allergic to glucosamine or any excipients in tablets;

3. patients who have been treated with glucosamine within three months;

4. patients who are unable to cooperate with the study;

5. continuous medication is less than 4 days;

6. patients with diarrhea, vomiting and other adverse reactions during medication.

Исход

Примарне мере исхода

1. Drug concentration in plasma [Fasting venous blood before the first administration]

Drug concentration is measured by HPLC-MS/MS

2. Drug concentration in plasma [3 hours after the third administration]

Drug concentration is measured by HPLC-MS/MS

3. Drug concentration in plasma [9 hours after the third administration]

Drug concentration is measured by HPLC-MS/MS

4. Drug concentration in plasma [Fasting venous blood before the fourth administration]

Drug concentration is measured by HPLC-MS/MS

5. Drug concentration in plasma [Venous blood during the operation of total knee arthroplasty]

Drug concentration is measured by HPLC-MS/MS

6. Drug concentration in synovial fluid [During the operation of total knee arthroplasty]

Drug concentration is measured by HPLC-MS/MS

7. Inflammatory markers in plasma [Fasting venous blood before the first administration]

Leptin

8. Inflammatory markers in plasma [3 hours after the third administration]

Leptin

9. Inflammatory markers in plasma [9 hours after the third administration]

Leptin

10. Inflammatory markers in plasma [Fasting venous blood before the fourth administration]

Leptin

11. Inflammatory markers in plasma [During the operation of total knee arthroplasty]

Leptin

12. Inflammatory markers in plasma [Fasting venous blood before the first administration]

IL-1β

13. Inflammatory markers in plasma [3 hours after the third administration]

IL-1β

14. Inflammatory markers in plasma [9 hours after the third administration]

IL-1β

15. Inflammatory markers in plasma [Fasting venous blood before the fourth administration]

IL-1β

16. Inflammatory markers in plasma [During the operation of total knee arthroplasty]

IL-1β

17. Inflammatory markers in plasma [Fasting venous blood before the first administration]

COX-2

18. Inflammatory markers in plasma [3 hours after the third administration]

COX-2

19. Inflammatory markers in plasma [9 hours after the third administration]

COX-2

20. Inflammatory markers in plasma [Fasting venous blood before the fourth administration]

COX-2

21. Inflammatory markers in plasma [During the operation of total knee arthroplasty]

COX-2

22. Inflammatory markers in plasma [Fasting venous blood before the first administration]

IL-6

23. Inflammatory markers in plasma [3 hours after the third administration]

IL-6

24. Inflammatory markers in plasma [9 hours after the third administration]

IL-6

25. Inflammatory markers in plasma [Fasting venous blood before the fourth administration]

IL-6

26. Inflammatory markers in plasma [During the operation of total knee arthroplasty]

IL-6

27. Inflammatory markers in plasma [Fasting venous blood before the first administration]

TNFα

28. Inflammatory markers in plasma [3 hours after the third administration]

TNFα

29. Inflammatory markers in plasma [9 hours after the third administration]

TNFα

30. Inflammatory markers in plasma [Fasting venous blood before the fourth administration]

TNFα

31. Inflammatory markers in plasma [During the operation of total knee arthroplasty]

TNFα

32. Inflammatory markers in plasma [Fasting venous blood before the first administration]

MMP-3

33. Inflammatory markers in plasma [3 hours after the third administration]

MMP-3

34. Inflammatory markers in plasma [9 hours after the third administration]

MMP-3

35. Inflammatory markers in plasma [Fasting venous blood before the fourth administration]

MMP-3

36. Inflammatory markers in plasma [During the operation of total knee arthroplasty]

MMP-3

37. Inflammatory markers in plasma [Fasting venous blood before the first administration]

ADAM-TS5

38. Inflammatory markers in plasma [3 hours after the third administration]

ADAM-TS5

39. Inflammatory markers in plasma [9 hours after the third administration]

ADAM-TS5

40. Inflammatory markers in plasma [Fasting venous blood before the fourth administration]

ADAM-TS5

41. Inflammatory markers in plasma [During the operation of total knee arthroplasty]

ADAM-TS5

42. Inflammatory markers in synovial fluid [During the operation of total knee arthroplasty]

Leptin

43. Inflammatory markers in synovial fluid [During the operation of total knee arthroplasty]

IL-1β

44. Inflammatory markers in synovial fluid [During the operation of total knee arthroplasty]

COX-2

45. Inflammatory markers in synovial fluid [During the operation of total knee arthroplasty]

IL-6

46. Inflammatory markers in synovial fluid [During the operation of total knee arthroplasty]

TNFα

47. Inflammatory markers in synovial fluid [During the operation of total knee arthroplasty]

MMP-3

48. Inflammatory markers in synovial fluid [During the operation of total knee arthroplasty]

ADAM-TS5

49. Gene polymorphism [Fasting venous blood before the first administration]

Gene polymorphisms of glucosamine transporters in vivo

Придружите се нашој
facebook страници

Најкомплетнија база лековитог биља подржана науком

  • Ради на 55 језика
  • Биљни лекови потпомогнути науком
  • Препознавање биљака по слици
  • Интерактивна ГПС мапа - означите биље на локацији (ускоро)
  • Читајте научне публикације повезане са вашом претрагом
  • Претражите лековито биље по њиховим ефектима
  • Организујте своја интересовања и будите у току са истраживањем вести, клиничким испитивањима и патентима

Упишите симптом или болест и прочитајте о биљкама које би могле да помогну, укуцајте неку биљку и погледајте болести и симптоме против којих се користи.
* Све информације се заснивају на објављеним научним истраживањима

Google Play badgeApp Store badge